COMMISSION WASHINGTON, D.C.

                                   FORM 12b-25

                           NOTIFICATION OF LATE FILING

|_|  Form 10-K and Form 10-KSB  |_| Form 20-F |_| Form 11-K
|X| Form 10-Q and Form 10-QSB   |_| Form N-SAR

         For Period Ended:  September 30, 2007

         |_| Transition Report on Form 10-K
         |_| Transition Report on Form 20-F
         |_| Transition Report on Form 11-K
         |_| Transition Report on Form 10-Q
         |_| Transition Report on Form N-SAR

         For the Transition Period Ended:

Read Attached Instruction Sheet Before Preparing form.  Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:

Part I - Registrant Information

Full Name of Registrant:   Interpharm Holdings, Inc.
Former Name if Applicable:

Address of Principal Executive Office:

75 Adams Avenue
Hauppauge, New York  11788

         (City, State and Zip Code)

Part II - Rules 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate.)

         |X|      (a) The reasons described in reasonable detail in Part III of
         this form could not be eliminated without unreasonable effort or

                  (b) The subject annual report, semi-annual report, transition
         report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof
         will be filed on or before the fifteenth calendar day following the
         prescribed due date; or the subject quarterly report or transition
         report on Form 10-Q, or portion thereof will be filed on or before the
         fifth calendar day following the prescribed due date; and

                  (c) The accountant's statement or other exhibit required by
         Rule 12b-25(c) has been attached if applicable.

Part III - Narrative

State below in reasonable detail the reasons why Form 10-K and Form 10-KSB,
20-F, 11-K, 10-Q and Form 10-QSB, N-SAR, or the transition report or portion
thereof could not be filed within the prescribed period.
                                                 (Attach Extra Sheets if Needed)

            Interpharm Holdings, Inc. (the "Company") requires additional time
to file its Quarterly Report on Form 10-Q in order to ensure the accuracy of the
information reported.

Part IV - Other Information

1. Name and telephone number of person to contact in regard to this

           Peter Giallorenzo                  (631) 952-0214
            Name)                       (Area Code) (Telephone Number)

2. Have all other periodic reports required under section 13 or 15(d) of the
Securities Exchange Act of 1934 or section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed. If the answer is no,
Identify report(s).

                                                                |X| Yes |_| No

3. It is anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

                                                                  |_| Yes |X| No

         If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.

         The information necessary to provide such an explanation is not
currently available.

                            Interpharm Holdings, Inc.
                  (Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date:         November 15, 2007             By:    /s/ Peter Giallorenzo
      -----------------------------             --------------------------------
                                                    Peter Giallorenzo
                                                    Chief Financial Officer and
                                                    Chief Operating Officer